cSCC & Immunotherapy: Managing Side Effects | Dr. Todd Schlesinger

Cutaneous squamous cell carcinoma (cSCC), a common form of skin cancer, is increasingly being treated with immunotherapies – drugs that help the body’s own immune system fight the cancer. Recent findings, as discussed by Todd Schlesinger, MD, suggest that patients generally tolerate these treatments well, but awareness of potential side effects is crucial. This development offers a promising avenue for managing advanced cSCC, particularly as multidisciplinary approaches become more common in treatment strategies.

Understanding Immunotherapy for cSCC

Immunotherapies, specifically PD-1 and PD-L1 agents, have shown improved outcomes for patients with cSCC. These agents work by blocking proteins that prevent the immune system from attacking cancer cells, essentially “releasing the brakes” on the immune response. This approach differs significantly from traditional cancer treatments like chemotherapy and radiation, which directly target cancer cells but can too harm healthy cells. The American Journal of Managed Care® recently highlighted these advancements, noting the positive impact of these therapies.

However, while generally well-tolerated, immunotherapies aren’t without potential adverse events. Understanding these is key for both patients and clinicians. The goal isn’t to instill fear, but to ensure proactive management and prompt reporting of any concerning symptoms.

What are the Common Adverse Events?

While Dr. Schlesinger’s comments focus on general tolerability, it’s important to understand that side effects can occur. These can range from mild to severe and vary depending on the individual and the specific immunotherapy used. Common adverse events associated with PD-1 and PD-L1 inhibitors include skin rashes, fatigue, diarrhea, and inflammation of various organs, such as the lungs (pneumonitis), liver (hepatitis), and endocrine glands (thyroiditis).

These side effects occur because the immune system, now activated, can sometimes attack healthy tissues in addition to cancer cells. This is known as an autoimmune reaction. The severity of these reactions can vary widely. For example, skin rashes might be mild and easily managed with topical creams, while pneumonitis can be life-threatening and require hospitalization and immunosuppressive treatment.

Who is Affected and What’s the Context?

cSCC is the second most common type of skin cancer, affecting an estimated hundreds of thousands of people globally each year. Risk factors include cumulative sun exposure, fair skin, a history of sunburns, and a weakened immune system. Advanced cSCC, which has spread beyond the skin, is particularly challenging to treat, making immunotherapies a valuable addition to the treatment arsenal.

The increasing use of multidisciplinary approaches, as discussed by Dermatology Times, involves collaboration between dermatologists, oncologists, surgeons, and other specialists to provide comprehensive care. This collaborative approach is particularly important for managing the complexities of advanced cSCC and its treatment with immunotherapies.

Evidence and Limitations of Current Findings

The positive outcomes observed with PD-1 and PD-L1 agents are based on clinical trials and real-world data. However, it’s important to acknowledge the limitations of this evidence. Clinical trials often involve carefully selected patients, and the results may not be generalizable to all individuals with cSCC. Long-term data on the durability of response and the potential for late-onset adverse events are still being collected.

It’s also crucial to understand that immunotherapy doesn’t work for everyone. Not all patients with cSCC will respond to these treatments, and identifying those most likely to benefit remains an area of ongoing research. Biomarkers, such as PD-L1 expression levels in tumor cells, are being investigated to help predict response, but their predictive value is not yet fully established. Drug Topics highlights the evolving landscape of treating skin cancers in the immunotherapy era, emphasizing the need for continued research and refinement of treatment strategies.

What Does This Mean for Patients?

For patients diagnosed with advanced cSCC, the availability of immunotherapies represents a significant advancement. These treatments offer the potential for durable responses and improved quality of life. However, patients should have a thorough discussion with their healthcare team about the potential benefits and risks of immunotherapy, as well as alternative treatment options.

It’s essential to report any new or worsening symptoms to your doctor promptly. Early detection and management of adverse events can help minimize their severity and ensure the continuation of treatment. Patients should also be aware of the importance of regular follow-up appointments to monitor for recurrence and assess long-term outcomes.

Looking Ahead: Ongoing Research and Guidance Updates

Research into immunotherapies for cSCC is ongoing, with a focus on identifying biomarkers to predict response, developing strategies to mitigate adverse events, and exploring combinations with other treatments. Clinical trials are evaluating novel immunotherapy agents and approaches, as well as the role of immunotherapy in earlier stages of cSCC.

Public health guidance regarding the use of immunotherapies for cSCC is continually evolving as new evidence emerges. Healthcare professionals should stay abreast of the latest recommendations from organizations such as the National Comprehensive Cancer Network (NCCN) and the American Academy of Dermatology (AAD). Patients can identify reliable information about cSCC and its treatment from reputable sources like the American Cancer Society and the Skin Cancer Foundation.

As our understanding of cSCC and immunotherapy deepens, we can expect to see further refinements in treatment strategies, leading to even better outcomes for patients. The key is a collaborative approach, combining the expertise of healthcare professionals with the active participation of informed patients.